Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Nieuwegein – page 73

2 029 clinical trials in Nieuwegein, The Netherlands across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Nieuwegein at a glance
2 029
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

2 029 trials in Nieuwegein

Open in trial search

Sickle cell disease

Not yet recruiting

A study of etavopivat to reduce vaso‑occlusive crises in children with sickle cell disease

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Etavopivat
  • Sponsor:Novo Nordisk A/S

Endometrial cancer

Not yet recruiting

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:GSK5733584
  • Sponsor:Glaxosmithkline Research & Development Limited

Hypertrophic cardiomyopathy

Not yet recruiting

Study of aficamten and 68Ga‑FAPI‑46 versus placebo in asymptomatic obstructive hypertrophic cardiomyopathy patients

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Aficamten
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Randomized Phase 3 Study of Deupirfenidone (LYT‑100) versus Pirfenidone in Adults with Idiopathic Pulmonary Fibrosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Deupirfenidone
  • Sponsor:Celea Therapeutics Inc.

Choroid melanoma

Not yet recruiting

Long‑Term Follow‑Up Study of Belzupacap Sarotalocan in Patients with Early Choroidal Melanoma

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Belzupacap Sarotalocan
  • Sponsor:Aura Biosciences Inc.

Optic ischaemic neuropathy

Not yet recruiting

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Epcoritamab plus rituximab versus rituximab alone in elderly, frail or unfit patients with newly diagnosed diffuse large B‑cell lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years
  • Substances:Epcoritamab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Acute myeloid leukaemia+2

Not yet recruiting

Safety and tolerability study of S-241656 with posaconazole in patients with AML, MDS/AML or CMML

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Posaconazole
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Neoplasm

Not yet recruiting

Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of MDMA hydrochloride therapy in adolescents aged 16‑18 with treatment‑resistant post‑traumatic stress disorder

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Midomafetamine Hydrochloride
  • Sponsor:Amsterdam UMC Stichting

Durvalumab after chemoradiation for patients with limited‑stage small cell lung cancer: a randomized trial of high‑dose versus standard thoracic radiation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Norwegian University Of Science And Technolology

Evaluating the efficacy and safety of CRD-4730 in patients with heart failure with reduced ejection fraction

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:CRD-4730
  • Sponsor:Cardurion Pharmaceuticals Inc.

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Nieuwegein

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focusing on idiopathic pulmonary fibrosis and related conditions, evaluating new therapeutic approaches for lung diseases. Studies include assessment of novel treatments for systemic autoimmune rheumatic diseases with lung involvement.

  • Pulmonary Fibrosis Treatment
  • Interstitial Lung Disease
  • Rheumatic Disease-Related Lung Conditions

Multiple trials are investigating both targeted therapies and comprehensive treatment approaches.

02 Oncology Research

Comprehensive studies in cancer treatment, particularly focusing on prostate cancer and urothelial cancer. Advanced imaging techniques and novel therapeutic combinations are being evaluated for improved patient outcomes.

  • Advanced Colorectal Cancer
  • Acute Myeloid Leukemia
  • Bladder Cancer Therapeutics

Trials are exploring personalized treatment approaches and innovative drug combinations.

03 Neurological Disorders

Research initiatives addressing status epilepticus and post-cardiac arrest care. Studies include innovative approaches for treating dementia and related behavioral issues.

  • Post-Cardiac Arrest Care
  • Dementia Management
  • Stroke Prevention

Investigations focus on both acute neurological conditions and long-term management strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.